Since mutations in these seed genes are very rare in previously published AML cohorts [10], they could trigger leukemogenesis only in this subset of AML patients which lack cytogenetic alterations and/or well-known molecular features that is, wild-type NPM1, CEBPA, and FLT3–ITD. Here, NPM1 is linked to acute myeloid leukemia.